Ocular Therapeutix, Inc. (OCUL) compared with its closest peers (XOMA, QTTB, AGIO, LXRX, NKTR). Peer set by Pharmaceutical Products; 10 comparable drugmakers. First-party data.
XOMA Royalty, Q32 Bio, Agios Pharmaceuticals, Lexicon Pharmaceuticals, Nektar Therapeutics, Aquestive Therapeutics, Cumberland Pharmaceuticals, Xilio Therapeutics, Journey Medical and Tango Therapeutics share Ocular Therapeutix's sub-industry, pharmaceutical makers.
| Company | Market Cap | P/E |
|---|---|---|
| XOMA Royalty Corp. (XOMA) | $505.65M | 16.8 |
| Q32 Bio Inc. (QTTB) | $270.79M | 1.4 |
| Agios Pharmaceuticals, Inc. (AGIO) | $1.97B | -3.8 |
| Lexicon Pharmaceuticals, Inc. (LXRX) | $1.03B | -8.1 |
| Nektar Therapeutics (NKTR) | $2.53B | -4.3 |
| Aquestive Therapeutics, Inc. (AQST) | $583.63M | -8.4 |
| Cumberland Pharmaceuticals Inc. (CPIX) | $114.10M | -20.5 |
| Xilio Therapeutics, Inc. (XLO) | $52.68M | -0.2 |
| Journey Medical Corporation (DERM) | $213.21M | -16.4 |
| Tango Therapeutics, Inc. (TNGX) | $3.46B | -10.2 |
| Sector P/E (Healthcare) | 21.7 |
| Industry P/E (Pharmaceutical Products) | 17.2 |
OCUL overview · OCUL earnings · OCUL financials · OCUL KPIs · OCUL documents · OCUL ownership
Data sourced from U.S. SEC EDGAR filings and market data. Not personalized investment advice.